Black Diamond Therapeutics (BDTX) Long-Term Deferred Tax (2019)

Black Diamond Therapeutics (BDTX) posted Long-Term Deferred Tax of $2.3 million for Q4 2019.

Black Diamond Therapeutics (BDTX) Long-Term Deferred Tax (2019) Analysis & Trends

Black Diamond Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $2.3 million for Q4 2019.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $2.3 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $2.3 million (changed N/A YoY) and the FY2019 annual result came in at $2.3 million, changed N/A from the prior year.
Long-Term Deferred Tax was $2.3 million for Q4 2019 at Black Diamond Therapeutics.
Across five years, Long-Term Deferred Tax topped out at $2.3 million in Q4 2019 and bottomed at $2.3 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Black Diamond Therapeutics	99.59 Mn	-18.67 Mn	-

Download Data

Date	Value
Dec 31, 2019	2.30 Mn